Magnesium and Vitamin D Supplementation and Cardiometabolic Outcomes
- Conditions
- Magnesium DeficiencyVitamin D DeficiencyCardiovascular Risk FactorOverweight and Obesity
- Interventions
- Dietary Supplement: Vitamin DDietary Supplement: Vitamin D and magnesiumDietary Supplement: Placebo
- Registration Number
- NCT03134417
- Lead Sponsor
- Drexel University
- Brief Summary
The purpose of this study is to investigate the effects of a combined vitamin D and magnesium supplementation on parathyroid hormone and cardiometabolic health in persons living with obesity.
- Detailed Description
Individuals living with obesity are at a higher risk of cardiometabolic abnormalities and high circulating parathyroid hormone. There is evidence suggesting that vitamin D may play a role in cardiovascular health outcomes; however, the research is currently inconclusive. Magnesium is a cofactor of vitamin D metabolism, and the prevalence of concurrent vitamin D and magnesium deficiency is high. This study aims to investigate the effect of vitamin D and magnesium supplements in individuals who are overweight and obese on parathyroid hormone and cardiometabolic health.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 109
- BMI range 25-40 kg/m2
- 30-70 years of age
- Presence of any acute illness in the past month
- Pre-existing chronic medical conditions or medications know to influence energy, vitamin D, magnesium and calcium metabolism, levels of blood glucose, lipids and blood pressure
- Individuals taking vitamin D and magnesium supplement greater than the Recommended Daily allowance
- Participants taking any medications or have disease known to influence calcium or bone metabolism
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Vitamin D Vitamin D Daily oral vitamin D (1000 IU) supplement Vitamin D and magnesium Vitamin D and magnesium Daily oral vitamin D (1000 IU) and magnesium (360 mg) supplement Placebo Placebo Daily oral placebo (cellulose)
- Primary Outcome Measures
Name Time Method Serum parathyroid hormone 12 weeks
- Secondary Outcome Measures
Name Time Method Lipid profile 12 weeks Inflammatory cytokines 12 weeks Blood pressure 12 weeks Serum osteocalcin 12 weeks
Trial Locations
- Locations (1)
Drexel University Nutrition Sciences Research Lab
🇺🇸Philadelphia, Pennsylvania, United States